The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity

AIM: Cariprazine, a dopamine D(3)‐preferring D(3)/D(2) receptor partial agonist, is FDA approved for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder. This study used in vivo electrophysiological techniques in anesthetized rats to determine cariprazine's effe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CNS Neurosci Ther
Main Authors: Delcourte, Sarah, Ashby, Charles R., Rovera, Renaud, Kiss, Béla, Adham, Nika, Farkas, Bence, Haddjeri, Nasser
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282959/
https://ncbi.nlm.nih.gov/pubmed/29729086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12867
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados